Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cecily J Forsyth"'
Autor:
Khai Li Chai, Cameron Wellard, LTP Thao, Naomi Aoki, Elizabeth M Moore, Bradley M Augustson, Akshay Bapat, Hilary Blacklock, Wee J Chng, Rachel Cooke, Cecily J Forsyth, Yeow‐Tee Goh, Nada Hamad, Simon J Harrison, P Joy Ho, Jay Hocking, Ian Kerridge, Jin Seok Kim, Kihyun Kim, Tracy King, Georgia J McCaughan, Peter Mollee, C Orla Morrissey, Nick Murphy, Hang Quach, Xuan Ni Tan, Allison CY Tso, Kimberly SQ Wong, Sung‐Soo Yoon, Andrew Spencer, Erica M Wood, Zoe K McQuilten
Publikováno v:
eJHaem, Vol 5, Iss 4, Pp 690-697 (2024)
Abstract Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in these patients. However, few real
Externí odkaz:
https://doaj.org/article/5a24a48b600f4da59acde72c4e4cde39
Autor:
Jacqueline N Khuong, Cecily J Forsyth, Lucy Manuel, Kate Kingsford-Smith, Arpit Srivastava, Levi Bassin
Publikováno v:
Perfusion. :026765912211091
Introduction Heparin resistance during cardiopulmonary bypass poses a significant intraoperative dilemma. Antithrombin deficiency related heparin resistance is well described, but less common causes are still poorly understood and inadequately manage
Publikováno v:
Medical Journal of Australia. 210:16
Publikováno v:
Thrombosis and Haemostasis. 86:1589-1590
Collection and Transport of Samples for Laboratory Testing in von Willebrand’s Disease (VWD): Time for a Reappraisal?
Autor:
David T. Yeung, Michael Osborn, Deborah L. White, Susan Branford, Lauren Haswell, Cassandra Slader, Samar Issa, Devendra K. Hiwase, Mark S. Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher K. Arthur, Yiu Lam Kwan, Cecily J. Forsyth, David M. Ross, Anthony K. Mills, Andrew Grigg, Timothy Hughes, on Behalf Of ALLG
Publikováno v:
Blood. 116:209-209
Abstract 209 Background: Although the majority of chronic phase (CP) Philadelphia positive (Ph+) chronic myelogenous leukemia (CML) patients (pts) achieve good disease control with imatinib, some pts demonstrate suboptimal responses. Early dose escal